These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 16028190

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
    Fox HC, McLean A, Turner JJ, Parrott AC, Rogers R, Sahakian BJ.
    Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
    [Abstract] [Full Text] [Related]

  • 3. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E, Daumann J.
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [Abstract] [Full Text] [Related]

  • 4. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?
    Morgan MJ, McFie L, Fleetwood H, Robinson JA.
    Psychopharmacology (Berl); 2002 Jan; 159(3):294-303. PubMed ID: 11862362
    [Abstract] [Full Text] [Related]

  • 5. A review of the acute subjective effects of MDMA/ecstasy.
    Baylen CA, Rosenberg H.
    Addiction; 2006 Jul; 101(7):933-47. PubMed ID: 16771886
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [Abstract] [Full Text] [Related]

  • 8. [A case of acute psychotic episode after a single dose of ecstasy].
    Vaiva G, Bailly D, Boss V, Thomas P, Lestavel P, Goudemand M.
    Encephale; 2001 Mar; 27(2):198-202. PubMed ID: 11407274
    [Abstract] [Full Text] [Related]

  • 9. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol.
    Indlekofer F, Piechatzek M, Daamen M, Glasmacher C, Lieb R, Pfister H, Tucha O, Lange KW, Wittchen HU, Schütz CG.
    J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709
    [Abstract] [Full Text] [Related]

  • 10. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low.
    Curran HV, Travill RA.
    Addiction; 1997 Jul; 92(7):821-31. PubMed ID: 9293041
    [Abstract] [Full Text] [Related]

  • 11. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    de Sola Llopis S, Miguelez-Pan M, Peña-Casanova J, Poudevida S, Farré M, Pacifici R, Böhm P, Abanades S, Verdejo García A, Langohr K, Zuccaro P, de la Torre R.
    J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
    [Abstract] [Full Text] [Related]

  • 12. Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review.
    Montoya AG, Sorrentino R, Lukas SE, Price BH.
    Harv Rev Psychiatry; 2002 Jul; 10(4):212-20. PubMed ID: 12119307
    [Abstract] [Full Text] [Related]

  • 13. The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans.
    Huxster JK, Pirona A, Morgan MJ.
    J Psychopharmacol; 2006 Mar; 20(2):281-90. PubMed ID: 16510486
    [Abstract] [Full Text] [Related]

  • 14. [Psychiatric and cognitive long-term effects of ecstasy].
    Høiseth G, Løvåsdal Ø, Titze TK, Bramness JG, Bachs L.
    Tidsskr Nor Laegeforen; 2006 Feb 23; 126(5):596-8. PubMed ID: 16505868
    [Abstract] [Full Text] [Related]

  • 15. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.
    Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A.
    Psychopharmacology (Berl); 2003 Apr 23; 167(1):85-96. PubMed ID: 12632248
    [Abstract] [Full Text] [Related]

  • 16. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users.
    Verheyden SL, Henry JA, Curran HV.
    Hum Psychopharmacol; 2003 Oct 23; 18(7):507-17. PubMed ID: 14533132
    [Abstract] [Full Text] [Related]

  • 17. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
    Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI.
    Pharmacol Rev; 2003 Sep 23; 55(3):463-508. PubMed ID: 12869661
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature.
    Uys JD, Niesink RJ.
    Drug Alcohol Rev; 2005 Jul 23; 24(4):359-68. PubMed ID: 16234132
    [Abstract] [Full Text] [Related]

  • 19. [Acute and long-term effects of ecstasy].
    Salzmann J, Marie-Claire C, Noble F.
    Presse Med; 2004 Oct 23; 33(18 Suppl):24-32. PubMed ID: 15617173
    [Abstract] [Full Text] [Related]

  • 20. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.
    Reneman L, Schilt T, de Win MM, Booij J, Schmand B, van den Brink W, Bakker O.
    J Psychopharmacol; 2006 May 23; 20(3):389-99. PubMed ID: 16574713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.